OBJECTIVES:
- To detect antibodies against NF155, nodal neurofascins (NF140, NF186) and CNTN1 in CIDP patients from a clinical trial(ICQ).
SAMPLES:
- For CNTN1: 0902-00881 (16), 0902-00887 (17), 0902-00890 (18), 0903-00852 (19), 0903-00855 (20), 0903-00856 (21), 0903-00880 (22), 0903-00889 (23), 0907-00860 (24), 0907-00871 (25), 0912-00898 (26), 0103-00902 (27), 0103-00905 (28), 0302-00894 (29), positive control.
- For NF140-186: 0902-00881 (16), 0902-00887 (17), 0902-00890 (18), 0903-00852 (19), 0903-00855 (20), 0903-00856 (21), 0903-00880 (22), 0903-00889 (23), 0907-00860 (24), 0907-00871 (25), 0912-00898 (26), 0103-00902 (27), 0103-00905 (28), 0302-00894 (29), positive control.
- For NF155: 0902-00881 (16), 0902-00887 (17), 0902-00890 (18), 0903-00852 (19), 0903-00855 (20), 0903-00856 (21), 0903-00880 (22), 0903-00889 (23), 0907-00860 (24), 0907-00871 (25), 0912-00898 (26), 0103-00902 (27), 0103-00905 (28), 0302-00894 (29), positive control.
- For NF155 con tag: 21-2-737, 21-2-739, c -, c+NF155.
- For NF155 sin tag: 21-2-737, 21-2-739, c -, c+NF155.
ICC CNTN1:
Blocking solution: Rabbit serum in PBS.
- Patient’s sera diluted 1/100 in rabbit sèrum in PBS.
- Primary antibody: anti-CNTN1 diluted 1/1000.
- Secondary antibodies: RAG 488 + RAH 594 (1/1000)
- Vectashield mounting medium.
ICC NF155/NF140/NF186:
Blocking solution: 5% goat serum in PBS.
- Patient’s sera diluted 1/100 in 5% goat serum in PBS.
- Primary antibody: anti-NF diluted 1/1000.
- Secondary antibodies: GAC488 + GAH 594 (1/1000).
- Vectashield mounting medium
RESULTS: All samples were negative. In CNTN1 wells hadn’t got cells.
